Juniper Genomics

Juniper Genomics

Formerly known as Embryome, health-tech company pioneering advanced embryo screening to enhance in vitro fertilization (IVF) outcomes.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor investor

€0.0

round
investor investor investor

€0.0

round
*

$4.6m

Seed
Total Funding000k
More about Juniper Genomics
Made with AI
Edit

Embryome leverages modern genomics and data science to assist individuals and couples trying to conceive, particularly those undergoing In Vitro Fertilization (IVF). The company aims to overcome the barriers and challenges faced by IVF patients by providing high-resolution genetic insights, which significantly improve the chances of achieving a term pregnancy with fewer IVF cycles. Embryome serves patients who are struggling with infertility and are seeking advanced reproductive technologies to enhance their chances of conception. Operating in the fertility treatment market, Embryome's business model revolves around offering specialized genomic testing and data-driven solutions to fertility clinics and patients. The company generates revenue through the sale of its genomic testing services and data analytics solutions, which are designed to optimize embryo selection and improve IVF outcomes. By focusing on reducing the number of IVF cycles required for a successful pregnancy, Embryome not only enhances patient satisfaction but also reduces the emotional and financial burden associated with multiple IVF attempts.

Keywords: genomics, data science, IVF, fertility, embryo selection, high-resolution genetics, reproductive technology, infertility, term pregnancy, IVF cycles.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads